Rezolute (RZLTD) Stock Price, News & Analysis

Company Overview

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $3.76 to $4.07
• 50-Day Range: $2.47 to $4.12
• 52-Week Range: $16.00 to $24.05
• Volume: 1.17 million shs
• Average Volume: 4,788 shs
• Market Capitalization: $32.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RZLTD Stock Analysis - Frequently Asked Questions

How have RZLTD shares performed this year?

Rezolute's stock was trading at $4.96 at the beginning of 2025. Since then, RZLTD shares have decreased by 22.8% and is now trading at $3.83.
View the best growth stocks for 2025 here.

How do I buy shares of Rezolute?

Shares of RZLTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RZLTD
• CIK: N/A
• Web: www.rezolutebio.com
• Phone: 650 206 4507
• Fax: N/A
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -153.46%
• Return on Assets: -111.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.24 per share
• Price / Book: 3.09

Miscellaneous

• Outstanding Shares: 8,418,000
• Free Float: N/A
• Market Cap: $32.24 million
• Optionable: Not Optionable
• Beta: 4.63